FR14C0069I1 - Composition pharmaceutique comprenant le lurasidone - Google Patents

Composition pharmaceutique comprenant le lurasidone

Info

Publication number: FR14C0069I1
Authority: FR; France
Prior art keywords: lurasidone; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2005-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sumitomo Pharma Co Ltd

Original Assignee

Sumitomo Dainippon Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-26

Filing date

2014-09-16

Publication date

2014-10-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0069(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-16 Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd

2014-10-24 Publication of FR14C0069I1 publication Critical patent/FR14C0069I1/fr

2015-11-20 Application granted granted Critical

2015-11-20 Publication of FR14C0069I2 publication Critical patent/FR14C0069I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Psychiatry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FR14C0069C 2005-05-26 2014-09-16 Composition pharmaceutique comprenant le lurasidone Active FR14C0069I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005153508		2005-05-26
PCT/JP2006/310571 WO2006126681A1 (fr)	2005-05-26	2006-05-26	Composition pharmaceutique

Publications (2)

Publication Number	Publication Date
FR14C0069I1 true FR14C0069I1 (fr)	2014-10-24
FR14C0069I2 FR14C0069I2 (fr)	2015-11-20

Family

ID=37452103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0069C Active FR14C0069I2 (fr)	2005-05-26	2014-09-16	Composition pharmaceutique comprenant le lurasidone

Country Status (22)

Country	Link
US (5)	US8729085B2 (fr)
EP (2)	EP2422783B1 (fr)
JP (2)	JP4733120B2 (fr)
KR (2)	KR101552033B1 (fr)
CN (2)	CN102048734B (fr)
AU (1)	AU2006250340C1 (fr)
BE (1)	BE2014C057I2 (fr)
BR (2)	BRPI0611409B8 (fr)
CA (1)	CA2606510C (fr)
CY (2)	CY1114118T1 (fr)
DK (2)	DK2422783T3 (fr)
ES (2)	ES2535478T3 (fr)
FR (1)	FR14C0069I2 (fr)
HU (1)	HUS1400051I1 (fr)
LU (1)	LU92550I2 (fr)
MX (1)	MX2007014872A (fr)
NL (1)	NL300690I2 (fr)
PL (1)	PL1884242T3 (fr)
PT (1)	PT1884242E (fr)
RU (1)	RU2398586C3 (fr)
SI (1)	SI1884242T1 (fr)
WO (1)	WO2006126681A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2633088T3 (es) *	2005-05-18	2017-09-19	Sumitomo Dainippon Pharma Co., Ltd.	Comprimido estable que contiene droxidopa
JP4733120B2 (ja) *	2005-05-26	2011-07-27	大日本住友製薬株式会社	医薬品組成物
US8673353B2 (en)	2008-02-11	2014-03-18	Dainippon Sumitomo Pharma Co., Ltd	Tablet having improved elution properties
CN102119034B (zh) *	2008-06-13	2013-05-22	大日本住友制药株式会社	在口腔中快速崩解的片剂和制备其的方法
JP5694773B2 (ja) *	2008-09-30	2015-04-01	テバ製薬株式会社	圧縮成型製剤およびその製造方法
SI3351240T1 (sl)	2009-05-19	2019-08-30	Celgene Corporation	Formulacije 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
KR101936968B1 (ko)	2010-10-18	2019-01-09	다이닛본 스미토모 세이야꾸 가부시끼가이샤	주사용 서방형 제제
WO2012063246A1 (fr) *	2010-11-11	2012-05-18	Mapi Pharma Ltd.	Forme amorphe du chlorhydrate de lurasidone
WO2012107890A2 (fr) *	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Formes cristallines de chlorhydrate de lurasidone
WO2012156981A1 (fr)	2011-05-13	2012-11-22	Cadila Healthcare Limited	Compositions pharmaceutiques de lurasidone
EP2736905A4 (fr)	2011-07-28	2015-07-29	Mapi Pharma Ltd	Composés intermédiaires et procédé pour la préparation de lurasidone et de sels de celle-ci
CN102911169B (zh) *	2011-08-02	2015-05-06	上海医药工业研究院	一种卢拉西酮的制备方法
WO2013061338A1 (fr)	2011-08-24	2013-05-02	Cadila Healthcare Limited	Compositions pharmaceutiques de silodosine
CN103446071B (zh) *	2012-05-29	2017-12-19	江苏豪森药业集团有限公司	一种口服片剂及其制备方法和用途
CN102688210A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮的药物组合物和制备方法
CN102688209A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮片和制备方法
CN106074414B (zh) *	2012-07-12	2019-01-18	成都康弘药业集团股份有限公司	一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) *	2012-12-06	2015-02-18	江苏先声药物研究有限公司	一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) *	2013-12-11	2015-06-11	Saravanan Kannusamy	Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (fr)	2014-07-25	2016-01-28	Lupin Limited	Composition pharmaceutique orale de lurasidone
CN104606133A (zh) *	2015-01-07	2015-05-13	万特制药(海南)有限公司	鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (fr) *	2015-03-05	2016-09-09	Jubilant Generics Limited	Compositions pharmaceutiques de lurasidone et son procédé de préparation
DE102016205950A1 (de) *	2016-04-08	2017-10-12	Dietrich Seidel	Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EA201991007A1 (ru) *	2016-11-02	2019-08-30	Сановель Илач Санайи Ве Тиджарет А.Ш.	Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CN108567758A (zh) *	2017-03-08	2018-09-25	湖南洞庭药业股份有限公司	盐酸鲁拉西酮片剂及其制备方法
MX2020001877A (es) *	2017-08-18	2020-09-14	Abbvie Inc	Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
CN107875122A (zh) *	2017-12-17	2018-04-06	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) *	2017-12-17	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) *	2017-12-19	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (fr)	2018-02-28	2019-09-06	大日本住友製薬株式会社	Préparation pharmaceutique de type suspension aqueuse à dissolution contrôlée
US20210378443A1 (en)	2018-04-10	2021-12-09	Z-Catering Mitte Gmbh	Method for conserving a meal prepared by heating, and for providing communal catering
WO2019199134A1 (fr) *	2018-04-13	2019-10-17	주식회사 삼양바이오팜	Composition pharmaceutique comprenant du lénalidomide
CN114340601A (zh) *	2019-09-25	2022-04-12	耐贝医药株式会社	掩盖了令人不快的味道的颗粒剂及其制造方法
CN115843243B (zh) *	2020-08-26	2025-09-05	浙江华海药业股份有限公司	盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) *	2020-12-03	2022-02-15	G L Pharma Gmbh	Feste orale pharmazeutische Zusammensetzung
EP4268816A4 (fr) *	2020-12-23	2024-12-04	Sumitomo Pharma Co., Ltd.	Préparation solide orale

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en)	1984-04-23	1985-11-05	National Starch And Chemical Corporation	Compressible starches as binders for tablets or capsules
US4609675A (en)	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en)	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
US5047246A (en)	1988-09-09	1991-09-10	Bristol-Myers Company	Direct compression cyclophosphamide tablet
US4911921A (en)	1989-02-02	1990-03-27	Mallinckrodt, Inc.	High ibuprofen content granulations
US5104648A (en)	1989-02-02	1992-04-14	Mallinckrodt Specialty Chemicals Company	High ibuprofen content granulations
JP2800953B2 (ja)	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
DK0812195T3 (da)	1995-02-28	2003-03-03	Aventis Pharma Inc	Farmaceutisk sammensætning til piperidinoalkanolforbindelser
JP4022269B2 (ja) *	1995-05-26	2007-12-12	協和醗酵工業株式会社	医薬組成物
CZ299018B6 (cs)	1997-10-20	2008-04-02	Dainippon Sumitomo Pharma Co., Ltd.	Rychlerozpustný farmaceutický prípravek
JP4063386B2 (ja) *	1998-01-29	2008-03-19	キッセイ薬品工業株式会社	速放性経口医薬品組成物
US6150366A (en)	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations
HK1044715B (zh) *	1999-03-31	2006-02-17	詹森药业有限公司	在控制释放制剂中的预胶凝淀粉
US6586617B1 (en)	1999-04-28	2003-07-01	Sumitomo Chemical Takeda Agro Company, Limited	Sulfonamide derivatives
AU2001246861A1 (en) *	2000-04-10	2001-10-23	Sumitomo Pharmaceuticals Co. Ltd.	Sustained release preparations
ATE431136T1 (de) *	2000-09-22	2009-05-15	Dainippon Sumitomo Pharma Co	Orale zubereitungen mit vorteilhaften zerfallseigenschaften
EP1371646B1 (fr)	2001-03-19	2010-05-19	Dainippon Sumitomo Pharma Co., Ltd.	Compose alicyclique a substitution aryle et composition medicale contenant ce compose
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
EP1535616B1 (fr) *	2002-08-22	2009-05-13	Dainippon Sumitomo Pharma Co., Ltd.	Medicament destine au syndrome de la dysfonction d'integration
AU2003304236A1 (en)	2002-08-30	2005-01-13	Pharmacia Corporation	Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
JPWO2004078173A1 (ja) *	2003-02-05	2006-06-08	塩野義製薬株式会社	溶出性の改善された錠剤
ES2737348T3 (es)	2003-09-12	2020-01-13	Amgen Inc	Formulación de disolución rápida que comprende cinacalcet HCl
CN1913876B (zh)	2003-12-09	2013-06-26	大日本住友制药株式会社	含药物的颗粒和包含这种颗粒的固体制剂
WO2006096439A2 (fr)	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
JP4733120B2 (ja)	2005-05-26	2011-07-27	大日本住友製薬株式会社	医薬品組成物

2006
- 2006-05-26 JP JP2007517921A patent/JP4733120B2/ja active Active
- 2006-05-26 CN CN2010105647842A patent/CN102048734B/zh not_active Expired - Fee Related
- 2006-05-26 ES ES11181100.6T patent/ES2535478T3/es active Active
- 2006-05-26 PL PL06746900T patent/PL1884242T3/pl unknown
- 2006-05-26 PT PT67469007T patent/PT1884242E/pt unknown
- 2006-05-26 CA CA2606510A patent/CA2606510C/fr active Active
- 2006-05-26 KR KR1020137027051A patent/KR101552033B1/ko active Active
- 2006-05-26 SI SI200631567T patent/SI1884242T1/sl unknown
- 2006-05-26 EP EP20110181100 patent/EP2422783B1/fr active Active
- 2006-05-26 BR BRPI0611409A patent/BRPI0611409B8/pt active IP Right Grant
- 2006-05-26 EP EP06746900.7A patent/EP1884242B1/fr active Active
- 2006-05-26 DK DK11181100.6T patent/DK2422783T3/en active
- 2006-05-26 KR KR1020077027270A patent/KR101380088B1/ko active Active
- 2006-05-26 US US11/919,678 patent/US8729085B2/en active Active
- 2006-05-26 WO PCT/JP2006/310571 patent/WO2006126681A1/fr not_active Ceased
- 2006-05-26 AU AU2006250340A patent/AU2006250340C1/en active Active
- 2006-05-26 RU RU2007148997A patent/RU2398586C3/ru not_active Application Discontinuation
- 2006-05-26 CN CN2006800182234A patent/CN101184489B/zh not_active Expired - Fee Related
- 2006-05-26 BR BR122020005056-0A patent/BR122020005056B1/pt active IP Right Grant
- 2006-05-26 DK DK06746900.7T patent/DK1884242T3/da active
- 2006-05-26 ES ES06746900T patent/ES2408687T3/es active Active
- 2006-05-26 MX MX2007014872A patent/MX2007014872A/es active IP Right Grant
2011
- 2011-03-18 JP JP2011061211A patent/JP5285105B2/ja active Active
2013
- 2013-05-14 CY CY20131100384T patent/CY1114118T1/el unknown
2014
- 2014-02-18 US US14/183,283 patent/US8883794B2/en active Active
- 2014-09-15 HU HUS1400051C patent/HUS1400051I1/hu unknown
- 2014-09-16 FR FR14C0069C patent/FR14C0069I2/fr active Active
- 2014-09-16 NL NL300690C patent/NL300690I2/nl unknown
- 2014-09-17 BE BE2014C057C patent/BE2014C057I2/fr unknown
- 2014-09-18 CY CY2014039C patent/CY2014039I2/el unknown
- 2014-09-18 LU LU92550C patent/LU92550I2/fr unknown
- 2014-10-10 US US14/512,189 patent/US9555027B2/en active Active
2015
- 2015-06-08 US US14/733,204 patent/US9907794B2/en active Active
2018
- 2018-02-06 US US15/889,893 patent/US20180161322A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2006126681A1 (fr)	2006-11-30
PT1884242E (pt)	2013-05-21
MX2007014872A (es)	2008-02-15
CN102048734B (zh)	2013-11-20
US20180161322A1 (en)	2018-06-14
BR122020005056A8 (pt)	2022-11-22
JP4733120B2 (ja)	2011-07-27
US9907794B2 (en)	2018-03-06
LU92550I2 (fr)	2015-11-02
JP5285105B2 (ja)	2013-09-11
DK1884242T3 (da)	2013-05-06
JP2011126915A (ja)	2011-06-30
CY2014039I1 (el)	2016-06-22
CY2014039I2 (el)	2016-06-22
BRPI0611409A2 (pt)	2010-11-23
CN102048734A (zh)	2011-05-11
HK1108379A1 (en)	2008-05-09
BE2014C057I2 (fr)	2025-12-10
CN101184489A (zh)	2008-05-21
EP1884242A1 (fr)	2008-02-06
EP2422783A1 (fr)	2012-02-29
US9555027B2 (en)	2017-01-31
BRPI0611409A8 (pt)	2015-12-15
EP1884242A4 (fr)	2009-07-01
NL300690I2 (nl)	2017-11-02
SI1884242T1 (sl)	2013-07-31
US20150056284A1 (en)	2015-02-26
BRPI0611409B1 (pt)	2020-12-29
KR101552033B1 (ko)	2015-09-09
HUS1400051I1 (hu)	2016-10-28
BR122020005056A2 (fr)	2010-11-23
US8729085B2 (en)	2014-05-20
EP2422783B1 (fr)	2015-04-08
KR101380088B1 (ko)	2014-04-10
BRPI0611409B8 (pt)	2021-05-25
AU2006250340C1 (en)	2014-06-12
EP1884242B1 (fr)	2013-04-17
CA2606510C (fr)	2014-07-22
US20140235651A1 (en)	2014-08-21
PL1884242T3 (pl)	2013-09-30
CN101184489B (zh)	2011-01-19
DK2422783T3 (en)	2015-05-11
RU2007148997A (ru)	2009-07-10
JPWO2006126681A1 (ja)	2008-12-25
RU2398586C2 (ru)	2010-09-10
ES2408687T3 (es)	2013-06-21
FR14C0069I2 (fr)	2015-11-20
AU2006250340A1 (en)	2006-11-30
US20150265611A1 (en)	2015-09-24
AU2006250340B2 (en)	2012-02-09
US8883794B2 (en)	2014-11-11
KR20130122019A (ko)	2013-11-06
KR20080012306A (ko)	2008-02-11
ES2535478T3 (es)	2015-05-12
CY1114118T1 (el)	2016-06-22
US20090143404A1 (en)	2009-06-04
CA2606510A1 (fr)	2006-11-30
RU2398586C3 (ru)	2017-10-04
BR122020005056B1 (pt)	2023-01-10

Publication	Publication Date	Title
FR14C0069I2 (fr)	2015-11-20	Composition pharmaceutique comprenant le lurasidone
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK1962873T3 (da)	2013-08-26	Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
EP2191826A4 (fr)	2010-09-15	Composition pharmaceutique
EP1748765A4 (fr)	2009-11-18	Suspension pharmaceutique
FR18C1032I2 (fr)	2019-08-09	Anticorps anti-fgf23 et composition pharmaceutique le comprenant
EP1982718A4 (fr)	2010-05-12	Composition pharmaceutique anticancereuse
EP2191828A4 (fr)	2010-09-15	Composition pharmaceutique antifongique
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
NL1029431A1 (nl)	2006-01-09	Vloeibare pesticidesamenstellingen.
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
EP1970076A4 (fr)	2012-12-12	Composition pharmaceutique pour application ungueale
DK1587478T3 (da)	2013-10-21	Farmaceutisk sammensætning
DK1957073T3 (da)	2014-05-12	Lægemiddel
ATE453384T1 (de)	2010-01-15	Neue dosierformulierung
DK3072507T3 (da)	2021-02-08	Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
FR2881643B1 (fr)	2008-12-05	Composition matifiante comprenant de la perlite
EP1871347A4 (fr)	2012-10-31	Preparation pharmaceutique
DK1741339T3 (da)	2014-05-12	Pesticid sammensætning
EP2116241A4 (fr)	2010-07-21	Composition pharmaceutique
EP1937255A4 (fr)	2013-06-26	Composition pharmaceutique
EP2224806A4 (fr)	2014-02-19	Composition pharmaceutique
EP1862184A4 (fr)	2012-12-19	Composition pharmaceutique